These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9860152)

  • 1. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
    Lucas RA; Gilfillan DJ; Bergstrom RF
    Eur J Clin Pharmacol; 1998 Oct; 54(8):639-43. PubMed ID: 9860152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine. Pharmacokinetic and pharmacodynamic profile.
    Callaghan JT; Bergstrom RF; Ptak LR; Beasley CM
    Clin Pharmacokinet; 1999 Sep; 37(3):177-93. PubMed ID: 10511917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Carrillo JA; Herráiz AG; Ramos SI; Gervasini G; Vizcaíno S; Benítez J
    J Clin Psychopharmacol; 2003 Apr; 23(2):119-27. PubMed ID: 12640212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.
    Linnet K; Olesen OV
    Ther Drug Monit; 2002 Aug; 24(4):512-7. PubMed ID: 12142636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam.
    Yasui-Furukori N; Kondo T; Kubota T; Otake H; Ohkubo T; Nagasaki T; Sugawara K; Chiba K; Otani K; Kaneko S
    Eur J Clin Pharmacol; 2001 Jul; 57(4):285-8. PubMed ID: 11549205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.
    Penzak SR; Hon YY; Lawhorn WD; Shirley KL; Spratlin V; Jann MW
    J Clin Psychopharmacol; 2002 Aug; 22(4):366-70. PubMed ID: 12172335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of fluoxetine on olanzapine pharmacokinetics.
    Gossen D; de Suray JM; Vandenhende F; Onkelinx C; Gangji D
    AAPS PharmSci; 2002; 4(2):E11. PubMed ID: 12102620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.
    Hägg S; Spigset O; Lakso HA; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):493-7. PubMed ID: 11699614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults.
    Darwish M; Bond M; Yang R; Hellriegel ET; Robertson P
    Clin Ther; 2015 Feb; 37(2):325-37. PubMed ID: 25438721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
    Rao ML; Hiemke C; Grasmäder K; Baumann P;
    Fortschr Neurol Psychiatr; 2001 Nov; 69(11):510-7. PubMed ID: 11704898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers.
    Markowitz JS; Devane CL; Liston HL; Boulton DW; Risch SC
    Clin Pharmacol Ther; 2002 Jan; 71(1):30-8. PubMed ID: 11823755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.
    Ring BJ; Binkley SN; Vandenbranden M; Wrighton SA
    Br J Clin Pharmacol; 1996 Mar; 41(3):181-6. PubMed ID: 8866916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.
    Olesen OV; Linnet K
    Ther Drug Monit; 1999 Feb; 21(1):87-90. PubMed ID: 10051059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience.
    Wrighton SA; Ring BJ
    Drug Metab Rev; 1999 Feb; 31(1):15-28. PubMed ID: 10065363
    [No Abstract]   [Full Text] [Related]  

  • 16. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.
    Licht RW; Olesen OV; Friis P; Laustsen T
    J Clin Psychopharmacol; 2000 Feb; 20(1):110-2. PubMed ID: 10653223
    [No Abstract]   [Full Text] [Related]  

  • 17. Urinary 6beta-hydroxycortisol/17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme induction.
    Konishi H; Tanaka K; Minouchi T; Yamaji A
    Ann Clin Biochem; 2004 Jul; 41(Pt 4):335-7. PubMed ID: 15298747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine.
    Boulton DW; Markowitz JS; DeVane CL
    J Chromatogr B Biomed Sci Appl; 2001 Aug; 759(2):319-23. PubMed ID: 11499485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine: interaction study with imipramine.
    Callaghan JT; Cerimele BJ; Kassahun KJ; Nyhart EH; Hoyes-Beehler PJ; Kondraske GV
    J Clin Pharmacol; 1997 Oct; 37(10):971-8. PubMed ID: 9505989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers.
    Shahzadi A; Javed I; Aslam B; Muhammad F; Asi MR; Ashraf MY; Zia-ur-Rahman
    Pak J Pharm Sci; 2011 Jan; 24(1):63-8. PubMed ID: 21190921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.